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Abstract 
Background: Anthracyclines and monoclonal antibodies against human epidermal growth factor receptor‑2 (HER2) 
are frequently used to treat breast cancer but they are associated with risk of developing cardiotoxicity. Implementa‑
tion of cardioprotective strategies as part of breast cancer treatment are needed. To date, a limited number of studies 
have examined the effectiveness of cardiac rehabilitation programs or exercise programs in the prevention of cardio‑
toxicity through an integral assessment of cardiac function. The ONCORE study proposes an exercise‑based cardiac 
rehabilitation program as a non‑pharmacological tool for the management of chemotherapy‑induced cardiotoxicity.
Methods: The study protocol describes a prospective, randomized controlled trial aimed to determine whether 
an intervention through an exercise‑based CR program can effectively prevent cardiotoxicity induced by anthra‑
cyclines and/or anti‑HER2 antibodies in women with breast cancer. Three hundred and forty women with breast 
cancer at early stages scheduled to receive cardiotoxic chemotherapy will be randomly assigned (1:1) to participa‑
tion in an exercise‑based CR program (intervention group) or to usual care and physical activity recommendation 
(control group). Primary outcomes include changes in left ventricular ejection fraction and global longitudinal strain 
as markers of cardiac dysfunction assessed by transthoracic echocardiography. Secondary outcomes comprise levels 
of cardiovascular biomarkers and cardiopulmonary function through peak oxygen uptake determination, physical 
performance and psychosocial status. Supervised exercise program‑related outcomes including safety, adherence/
compliance, expectations and physical exercise in‑ and out‑of‑hospital are studied as exploratory outcomes. Tran‑
sthoracic echocardiography, clinical test and questionnaires will be performed at the beginning and two weeks after 
completion of chemotherapy.
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Background
Survival in breast cancer has improved due to advances 
in early detection and treatment, leading to reduced 
breast cancer-related mortality [1]. However, many of 
the current cancer therapies are linked to multiple side 
effects. Of these treatments, chemotherapy has been 
associated with adverse cardiovascular events, such as 
decreased cardiac function, heart failure, coronary artery 
disease, arterial hypertension or thromboembolism [2, 
3]. In fact, cardiovascular disease is the leading cause of 
death among women with early-stage breast cancer [4]. 
The absolute risk of dying from cardiovascular disease 
in breast cancer ranges from 1.6 to 10.4% [5], and it is 
higher than that of women from the general population 
[5, 6]. Treatment using anthracyclines and monoclonal 
antibodies against human epidermal growth factor recep-
tor 2 (HER2) has resulted in substantial improvements 
in survival, but these agents have been associated with 
the development of cardiotoxicity [7, 8]. Cardiotoxicity 
is defined by either a decrease in left ventricular ejec-
tion fraction (LVEF) above 10% from baseline to a value 
of LVEF under 53%, or a decrease in global longitudinal 
strain (GLS) deformation below 15% from baseline value 
[9, 10]. While transthoracic echocardiography (TTE) is 
the standard method to evaluate cardiotoxicity [9], com-
prehensive assessment of cardiac function may include 
other tests, such as biomarkers (troponin I and B-type 
natriuretic peptide) [11] and cardiopulmonary func-
tion measured by peak oxygen uptake (VO2). The latter 
is considered as a gold standard parameter, which may 
decrease by 5–26% during exposure to various treatment 
regimens [12]. The combination of global and specific 
measures of cardiac function allows identifying patients 
at risk of heart failure more accurately and initiating 
appropriate treatment [13, 14]. To respond to this chal-
lenge, Cardio-Onco-Hematology (COH) units for early 
diagnosis and treatment have emerged [12, 15].
Exercise programs are increasingly being recognized 
as an effective strategy to counteract adverse effects 
of cancer therapy [16–19]. While there is extensive 
evidence on the benefits of exercise to mitigate side 
effects such as fatigue [20] or to improve quality of life 
[21], evidence on the cardioprotective effects of exer-
cise in breast cancer is still limited [4, 22–24]. In addi-
tion to exercise programs, cardiac rehabilitation (CR) 
programs have proven beneficial to lessen the conse-
quences of cardiovascular disease and reduce the risk of 
future events [25]. CR programs perform a comprehen-
sive evaluation of cardiovascular risk and a multi-fac-
eted intervention including dietary counselling, weight 
and blood pressure control, lipid profile optimisation, 
smoking cessation, psychosocial support, adherence to 
medical treatment and structured exercise therapy as a 
central component [26]. Participation in structured CR 
programs is associated with reduced mortality after an 
acute coronary event [27], and also with improvement 
of event-free survival in patients with heart failure [28]. 
Nonetheless, programs based on CR are not yet stand-
ardized within breast cancer care [29].
The main aim of this study is to determine whether 
an intervention through an exercise-based CR pro-
gram could effectively prevent cardiotoxicity induced 
by anthracyclines and/or anti-HER2 antibodies in 
women with breast cancer at early stages, as compared 
with usual care and physical activity recommenda-
tion. Secondary aims are to determine the effect of the 
intervention on other cardiac function parameters (car-
diopulmonary function assessed by peak VO2 and bio-
markers), physical performance outcomes (e.g., body 
composition, limb strength and upper limb function); 
and psychometric and lifestyle outcomes (e.g., quality 
of life, physical exercise, diet pattern). Furthermore, 
safety of the intervention and supervised exercise pro-
gram outcomes (adherence-compliance, expectations, 
satisfaction) are also assessed.
We hypothesize that an exercise-based CR program 
will be effective in preventing chemotherapy-induced 
cardiotoxicity in women with breast cancer at early 
stages, compared to usual care and physical exercise rec-
ommendation. Moreover, we hypothesize that patients 
in the intervention group will maintain or improve their 
physical performance and psychosocial status.
Discussion: The growing incidence of breast cancer and the risk of cardiotoxicity derived from cancer treatments 
demand adjuvant cardioprotective strategies. The proposed study may determine if an exercise‑based CR program 
is effective in minimizing chemotherapy‑induced cardiotoxicity in this population of women with early‑stage breast 
cancer. The proposed research question is concrete, with relevant clinical implications, transferable to clinical practice 
and achievable with low risk.
Trial registration ClinicalTrials.gov Identifier: NCT03964142. Registered on 28 May 2019. Retrospectively registered. 
https:// clini caltr ials. gov/ ct2/ show/ NCT03 964142
Keywords: Breast cancer, Cardiotoxicity, Cardiac rehabilitation, Exercise, Cardio‑oncology, Anthracyclines, HER2 
overexpression
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Methods
This study protocol follows the SPIRIT 2013 [30] rec-
ommendations, an additional checklist file shows this 
in more detail (Additional file  1). This is a two-arm, 
prospective, randomized controlled trial comparing an 
exercise-based CR program (experimental group) to 
usual care and physical activity recommendation (con-
trol group) in women receiving anthracycline and/or 
anti-HER2 antibodies for early breast cancer. The trial is 
conducted based on the coordinated work of the COH 
and the CR and Preventive Cardiology units at the Uni-
versity Clinical Hospital of Santiago de Compostela 
(Galicia, Spain). The design of the trial is shown in Fig. 1. 
The study has been approved by the Ethics Committee of 
Clinical Investigation of Galicia (CEIC reference number 
2018/083). Financial support for this work is provided 
by the Carlos III Health Institute (ISCIII)—PI17/01687, 
co-funded FEDER, through a competitive grant of the 
Healthcare Research Fund, under the Strategic Health 
Action call for proposals.
Study duration and timing
The study timeline is depicted in Fig. 2. Patient recruit-
ment and data collection started in August 2018. The 
inclusion and baseline assessment of patients is carried 
out progressively as they start treatment with cardiotoxic 
chemotherapy including anthracyclines and/or anti-
HER2 antibodies, adjusting to the reality of routine clini-
cal practice. The intervention lasts until the last patient 
recruited finishes the cardiotoxic treatment, between 
6 and 12  months, depending on whether this includes 
anti-HER2 antibodies. Post-treatment assessment is 
performed two weeks after the last cycle of cardiotoxic 
chemotherapy including anti-HER2 antibodies. Data 
collection is expected to be completed in March 2022 
when all patients in the study will have completed their 
respective treatments and undergone post-treatment 
assessment.
Recruitment and inclusion
The study population consists of female patients aged 
between 18 and 70 years with a first diagnosis of breast 
cancer at early stages (I, II, III), who are planned to 
receive anthracyclines and/or anti-HER2 antibodies 
(trastuzumab and pertuzumab), without contraindica-
tions to join a CR program or to complete the scheduled 
visits and providing written consent to participate. If 
patients are referred once chemotherapy has been initi-
ated, only those who have received less than 20% sessions 
of the cardiotoxic treatment planned will be eligible for 
the study. Inclusion and exclusion criteria are detailed 
in Table  1. Potential participants are detected in daily 
practice among patients referred to the COH unit to 
undergo the established protocol to identify cardiotoxic-
ity (clinical, laboratory and echocardiographic follow-up 
assessment). COH specialists are responsible for initial 
screening, providing information about the study and 
offering informed consent to patients.
Randomization
After signing the informed consent and undergoing ini-
tial assessment, patients are randomized to the experi-
mental group (EG) or the control group (CG) by simple 
randomization performed by an external person using a 
computer-generated number sequence. The physiothera-
pist is responsible for informing each patient of the fol-
low-up modality. The EG will join an exercise-based CR 
program, while the CG will receive conventional manage-
ment and physical activity recommendation.
Intervention
Experimental group: exercise‑based CR program
The intervention in the EG consists of a supervised exer-
cise-based CR program undergone during chemotherapy, 
which can be administrated before (neoadjuvant) and/or 
after (adjuvant) surgery. The supervised exercise program 
takes place at the hospital CR room and is guided and 
supervised by a physiotherapist, in groups of 7 partici-
pants twice a week. Each 1-h session will comprise four 
parts.
• First part: 15 min of breathing, mobility and balance 
exercises developed through 8 exercise with 1 set of 
7–10 repetitions.
• Second part: 15 min of strength exercises consisting 
of 4 bodyweight exercises with 2 sets of 7–10 repeti-
tions and 5 resistance bands exercises with 2 sets of 
7–10 repetitions.
• Third part: 25 min of continuous or interval exercise 
in the aerobic-anaerobic transition zone using a cycle 
ergometer or a treadmill. The patients are monitored 
with telemetry (Ergoline ERS 2, Germany). A target 
of 50–85% of heart rate reserve, according to the car-
diopulmonary exercise testing (CPET), will be aimed. 
This objective may be adjusted according to patient’s 
perceived exertion to rate subjective fatigue values 
between 3 and 7 (Borg Scale 0–10) and the physi-
otherapist’s criteria.
• Fourth part: 5 min of flexibilization including 6 types 
of exercises for the major muscle groups.
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Fig. 1 Flowchart ONCORE design
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Patients in the EG are offered to request an appointment 
with the CR psychologist if needed. Sessions are held 
individually for about one hour.
Control group: usual care and physical activity 
recommendation
Participants in the CG receive conventional manage-
ment with general physical activity recommendation. 
The physiotherapist performs a clinical interview by 
telephone every two months until final assessment.
Common intervention for both groups
All patients receive the same supervision within the 
COH unit, every 2  months since the beginning of the 
treatment, including cardiotoxicity detection and car-
diovascular risk factor control, consisting of dietary 
advice, smoking cessation, lipid profile, blood pressure 
control and cardiovascular medical treatment opti-
mization. In addition, a practice guide with exercise 
recommendations and an exercise routine example is 
provided, as well as an exercise diary to register physi-
cal exercise (including date, minutes and type of exer-
cise done) on a daily basis. Participants in both groups 
are encouraged and reminded of the importance of 
adherence to physical exercise.
Criteria for drop out
Criteria for discontinuing allocated interventions are 
participant’s will to revoke participation in the study, 
Fig. 2 Study timeline
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Woman aged > 18 years and < 70 years Patients with previous history of heart disease or heart failure
First diagnosis of breast cancer at early stages (I, II, III) Left ventricular dysfunction (left ventricular ejection fraction < 53%) at 
baseline
Patients who will receive adjuvant or neoadjuvant treatment with curative 
intention
Metastatic disease
Treatment with anthracyclines and/or anti‑HER‑2 antibodies (trastuzumab 
and pertuzumab)
Patients carrying an implantable cardioverter defibrillator
Possibility of completing a cardiac rehabilitation program and pro‑
grammed visits
Patients with physical or mental limitation to carry out an exercise program
Providing written informed consent Refuse to participate
Overcome 20% of cardiotoxic treatment
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worsening of oncological prognosis that prevents 
the continuation and absence of training sessions for 
unjustified reasons in the case of the EG (below 60% 
compliance).
Study outcomes
Outcomes measures and assessment methods are sum-
marized in Table  2. Primary and secondary outcomes 
are assessed at the beginning and two weeks after com-
pletion of chemotherapy. Exploratory outcomes are 
collected post treatment. The COH specialists perform 
echocardiographic evaluation and scheduled blood 
Table 2 Study outcome measure
LVEF left ventricular ejection fraction, GLS global longitudinal strain, TTE transthoracic echocardiography, CPET cardiopulmonary exercise test, NT- proBNP N‑terminal 
brain natriuretic propeptide, BMI body mass index, BPM blood pressure monitor, SPADI shoulder pain and disability index, PREDIMED PREvención con DIeta 
MEDiterránea, FACT-B + 4 functional assessment of cancer therapy—breast plus arm morbidity, HADS hospital anxiety and depression scale, GLTEQ Godin Leisure Test 
Exercise Questionnaire, EG experimental group
Domain Measure Assessment Method Timepoint from chemotherapy
Primary outcomes
Cardiotoxicity Resting LVEF TTE Pre‑post
Resting GLS TTE Pre‑post
Secondary outocomes
Cardiopulmonary function VO2 peak CPET Pre‑post
Biomarkers NT‑ proBNP Blood test Pre‑post
Troponin I Blood test Pre‑post
Hemoglobin Blood test Pre‑post
Body composition % Body fat Tanita Pre‑post
% Lean mass Tanita Pre‑post
Anthropometrics Height Height road Pre
Weight Tanita Pre‑post
Abdominal circumference Tape measure Pre‑post
BMI Database Pre‑post
Vital signs Heart rate BPM Pre‑post
Blood pressure BPM Pre‑post
Cardiovascular risk factors Dyslipidemia Clinical history Pre‑post
Diabetes mellitus Clinical history Pre‑post
Arterial hypertension Clinical history Pre‑post
Smoking status Clinical interview Pre‑post
Limb strength Lower limb strenght 30‑STS Pre‑post
Uper limb strenght Handgrip dinamometry Pre‑post
Upper limb function in women undergone surgery Limb perimeters Tape measure Pre and/or post if surgery
Shoulder functional capacity Goniometry Pre and/or post if surgery
Shoulder pain and disability SPADI Pre and/or post if surgery
Psychometric and lifestyle questionnaires Anxiety and depression HADS Pre‑post
Health‑related quality of life FACT‑B + 4 Pre‑post
Level of physical activity GLTEQ Pre‑post
Adherence mediterranean diet PREDIMED Pre‑post
Exploratory outcomes
Physical exercise Minutes of In‑ (EG) and out‑ (both 
groups) of‑hospital dedicated 
exercise
Exercise diary Post
Safety of the intervention Adverse events during exercise 
and clinical serious adverse 
events
Medical history and 
reported information
Post
Supervised exercise program Adherence and compliance Attendance register Post
Expectations Open question Post
Satisfaction 9‑item questionnaire Post
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tests. The CR and Preventive Cardiology specialists 
perform the other evaluation components, including 
cardiopulmonary function, physical performance and 
biopsychosocial aspects.
Primary outcomes
Cardiotoxicity is defined by either a significant decrease 
of LVEF or GLS, as previously described (9). GLS is 
included as it is an early and more sensitive indicator of 
subclinical heart failure, while a decrease in LVEF repre-
sents more advanced stages of the disease [10]. The pres-
ence of episodes of heart failure will be recorded. LVEF 
is calculated using Simpson’s biplane rule from the apical 
4- and 2-chamber view and GLS is obtained by speckle-
tracking analysis of 4-, 3- and 2- chamber view with 
2-dimensional echocardiography. Echocardiographic 
measurements are performed with GE Vivid E95 (GE 
Vingmed Ultrasound AS, Horten, Norway) ultrasound 
system by the same experienced operator and doubled 
checked by a cardiac imaging expert, both of whom are 
blinded to the clinical data.
A broader assessment of cardiotoxicity includes the 
full spectrum of cardiovascular complications of cancer 
treatment and considers other diagnostic options [9, 11], 
as reflected in the secondary outcomes section.
Secondary outcomes
Other cardiac function outcomes
• Cardiopulmonary function: peak VO2 (ml/kg/min), 
percentage of predicted peak VO2 (%ppVO2) and 
metabolic equivalents of task (METs) are assessed 
by CPET on a continuous incremental test in a cycle 
ergometer (CardioWise Ergo Fit, Pirmasens, Ger-
many), with workload calculated for each patient 
depending on body mass, age and fitness.
• Biomarkers: biomarkers of myocardial damage 
including N-terminal brain natriuretic propeptide 
(NT-proBNP) and troponin I and hemoglobin (g/dl) 
are determined on a blood sample.
Body composition, anthropometrics and vital signs
Body composition, including % body fat and lean mass, 
are assessed by electrical bioimpedance (Tanita MC 
780P-MA). Anthropometrics include assessment of: 
height, weight, abdominal circumference and body mass 
index (BMI). Vital signs, including heart rate and blood 
pressure, are assessed with a blood pressure monitor 
(Omron M3 IT).
Cardiovascular risk factors
The presence of dyslipidemia, diabetes mellitus, arte-
rial hypertension and smoking status are checked on the 
electronic clinical history and through clinical interview.
Limb strength and upper limb function
Lower limb strength is assessed by the number of 
repetitions in a 30-s sit-to-stand test; and upper limb 
strength (in kg) is measured in both arms using hand-
grip dynamometry (Jamar Hydraulic Hand Dynamom-
eter). Upper limb function evaluation in women who 
have undergone breast surgery or lymphadenectomy 
is conducted measuring upper limb perimeters for the 
detection of lymphedema [32]; shoulder functional 
capacity assessed by range of motion by goniometry 
[33]; and shoulder pain and disability assessed by the 
Shoulder Pain And Disability Index (SPADI) question-
naire [34].
Psychometric status and healthy lifestyle habits
Anxiety and depression is assessed by the Hospital Anxi-
ety and Depression Scale (HADS) [35]. The Health-
related quality of life by the Functional Assessment of 
Cancer Therapy—Breast plus Arm Morbidity (FACT-
B + 4) questionnaire [36]. The level of physical activity 
is quantified through the Godin Leisure Test Exercise 
Questionnaire (GLTEQ) expressed as METs/week [37]. 
Adherence to Mediterranean diet with the PREDIMED 
(PREvención con DIeta MEDiterránea) questionnaire 
[38].
Exploratory outcomes
Physical exercise performed out of hospital by partici-
pants in both groups is registered in an exercise diary 
addressing modality (aerobic, strength, flexibility) and 
exercise duration (minutes). Additionally, supervised 
exercise performed in-hospital by participants in the EG 
is recorded by the physiotherapist.
Safety of the intervention is monitored by the number 
of adverse events occurred during supervised exercise 
sessions and other clinical serious adverse events (e.g., 
anaemia, neutropenia, episodes of heart failure) accord-
ing to the Common Terminology Criteria for Adverse 
Events version 4.0 (CTCAE v.4.0) [39].
Adherence to the intervention is defined as the rate 
of patients completing the program out of those who 
initiate it, and compliance rate is defined by the num-
ber of exercise sessions attended divided by the number 
of sessions planned. Finally, program-related expecta-
tions are assessed at baseline and at the end of the pro-
gram through an open question ("What do you expect 
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to achieve by participating in the program?”), with 
responses being categorized into psychological, social 
and physical spheres. Satisfaction at the end of the pro-
gram is evaluated by a 9-item questionnaire designed ad 
hoc.
Data management
Data is collected electronically through an encrypted 
online database designed for each study procedure 
(screening, initial/final assessment, etc.). No identifica-
tion data is recorded in the database, but an identifica-
tion number is assigned to each patient. This number is 
associated to the patient’s clinical history number in an 
independent table only accessible to the ONCORE inves-
tigators on a corporate computer. All the information 
handled is dissociated from the patient’s identification 
information (pseudonymized) and only ONCORE inves-
tigators will have access to the identification details.
Blinding
The type of intervention performed precludes blind-
ing patients or staff involved. Thus, although the pro-
fessionals involved in the initial assessment (before 
randomization) are blinded, only those who perform the 
echocardiogram and the registration of biomarkers are 
blinded in the final assessment.
Sample size calculation
Considering the main variable of analysis "develop-
ment of cardiotoxicity" [9], sample size is determined 
by comparing two independent proportions to examine 
the effect of an exercise-based CR program. Based on 
an expected prevalence of cardiotoxicity in the CG of 
20% [31] and 10% in the EG, a variation of 10% between 
groups is detected, that is, an expected cardiotoxicity 
prevention of 50% in the EG. The Marrugat et al. [40] for-
mula was used for sample size estimation, accepting an 
alpha risk of 0.05 and a statistical power of 80%, resulting 
in the need to recruit 154 participants in each arm. With 
an expected 10% rate of patients who will not complete 
the treatment or drop out, it will be necessary to include 
a total of 340 patients (experimental arm: n = 170; usual 
care: n = 170).
Statistical analysis
Analyses will be conducted with SPSS v.25 and R v.4.0.2. 
software. Both approaches intention to treat and per-
protocol analysis will be used. Descriptive analyses will 
comprise calculating the mean, median, standard devia-
tion, interquartile range for quantitative variables, and 
absolute and relative frequencies for categorical vari-
ables. Distribution and normality of the variables will be 
determined by one-sample Kolmogorov–Smirnov tests 
for a sample (significance < 0.05). To detect differences in 
changes between groups, the data will be analysed using 
Student’s T or ANOVA for parametric variables and with 
the Wilcoxon test for non-parametric variables. Also 
effect size will be calculated to see the variance between 
both groups.
Additionally, correlation and regression analyses will be 
performed to determine whether the echocardiographic 
parameters are significantly associated with the changes 
in cardiopulmonary function, physical performance (e.g., 
muscle strength), and psychometric status (e.g., quality of 
life) and lifestyle habits (e.g., diet).
Dissemination
The trial results will be submitted for publication in a 
peer-reviewed clinical journal without restrictions and 
presented at relevant conferences. The investigation will 
be part of a doctoral thesis project signed by the first 
author.
Discussion
This protocol describes a randomized controlled study 
to examine the effect of an exercise-based CR program 
on the prevention of chemotherapy-induced cardiotox-
icity assessed by echocardiographic parameters (LVEF 
and GLS), compared with conventional management. 
Cardiovascular disease is increasing among women with 
breast cancer and becoming a leading causes of death [4, 
12]. Gernaat et al. [5] reported an absolute risk from 1.6 
to 10.4% in breast cancer survivors. The increasing use 
of cardiotoxic treatments, such as anthracyclines and 
anti-HER2 antibodies, together with cardiovascular risk 
factors, are the main cause of cardiovascular health wors-
ening. Asymptomatic cardiac dysfunction defined by a 
subclinical decrease of LVEF, has been associated with 
a higher incidence of symptomatic heart failure, which 
occurs in up to 20% of patients depending on treatment 
regimen [31]. Therefore, other parameters such as GLS, 
biomarkers or VO2 are considered to increase the sensi-
tivity in the subclinical detection of cardiotoxicity [12].
Coordinated efforts in the early diagnosis of cardio-
toxicity within COH units present an opportunity for 
the study of pharmacological and non-pharmacological 
strategies to prevent it. Exercise-based CR programs are 
a ready-to-use resource and can be a valid non-phar-
macological treatment strategy, potentially extendable 
to cancer patients. This network highlights the need for 
a multidisciplinary group of professionals working in an 
integrated care process. Exercise-based CR programs 
offer a comprehensive approach, with cardiovascular risk 
factors management, psychosocial support and healthy 
lifestyle counseling. This therapy modality encour-
ages patients to have an active role in their therapeutic 
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process, contributing to increase their perception of con-
trol [41].
Exercise, pointed out as a core component of these 
programs, has been shown to be safe and effective in 
mitigating side effects of breast cancer treatment, such 
as worsening quality of life [21], fatigue [20] or decreased 
physical function [42]. However, several studies have 
highlighted the need for more evidence on the cardio-
protective effects of exercise in preventing cardiotoxic-
ity and improving cardiopulmonary function [4, 12, 29, 
43]. Among studies applying an exercise program and 
evaluating heart function [43–49], broad differences are 
described for (1) sample size; (2) the period of applica-
tion of the intervention (during or after treatment); (3) 
outcomes (echocardiographic parameters, peak VO2, 
biomarkers, cardiovascular risk factors, etc.); and (iv) 
evaluation methods (echocardiography, cardiopulmo-
nary exercise testing, indirect estimation of VO2, blood 
tests, etc.). In addition, some studies [45, 50, 51] and 
protocols [52–54] have taken into account a broad spec-
trum of measurements for cardiac function assessment. 
Kirkham et al. [50] analysed the efficacy of a single aer-
obic bout performed 24  h prior to each anthracycline 
treatment in the prevention of breast cancer cardiotoxic-
ity. These authors did not observe a relevant effect of the 
intervention on the reduction of subclinical cardiotoxic-
ity (echocardiographic or circulating cardiac biomark-
ers outcomes) but did observe a positive systemic effect 
comprising hemodynamic adaptations, positive psycho-
logical effects, improved body musculoskeletal symptoms 
and body weight reduction. In turn, a non-randomized 
trial conducted by Howden et al. [12] examined the car-
dioprotective effect of a supervised exercise program 
(2  days/week supervised and 1  day/week unsupervised) 
in women with breast cancer receiving anthracyclines. 
They found an attenuation of the decrease in VO2 and 
higher levels of troponin in the exercise group compared 
to the usual care group, but no relevant changes were 
observed in echocardiographic outcomes. Otherwise, 
in a randomized controlled trial, Hojan et  al. [51] com-
pared a 5-day/week exercise program for 9  weeks with 
usual care in women with HER2 positive breast cancer, 
noting a protective effect of the exercise program on 
reducing LVEF and cardiopulmonary function assessed 
by 6-min walking test, while on plasma parameters they 
did not find significant differences. Thus, the role of exer-
cise in preventing chemotherapy-induced cardiotoxic-
ity remains unclear. The ONCORE study attempts to 
elucidate how an exercise-based CR program may con-
tribute to prevent cardiotoxicity in this setting. To this 
effect, this randomized study includes a larger sample of 
patients and performs a comprehensive assessment of 
cardiac function combining TTE, CPET and biomarkers, 
along with the monitoring of cardiovascular risk factors. 
In addition, the effects on psychosocial health and physi-
cal performance are recorded.
This study has limitations that should be underlined. 
First, although radiotherapy is also a cardiotoxic treat-
ment [55], it has not been considered as an inclusion 
criterion alone. This implies that at the end of the study 
some patients would have received radiotherapy and 
others would have not. Therefore, radiotherapy sessions 
received by every patient are recorded for appropriate 
adjustments. On the other hand, as the overexpres-
sion of HER2 occurs in approximately 15–20% of breast 
cancers [56], the follow-up time in the CR program 
may differ between patients receiving different treat-
ment schemes, being an expected source of heteroge-
neity. Given the long duration of the study, especially 
in patients followed for more than 12  months (HER2 
positive), a higher risk of dropout is expected. How-
ever, a lengthy intervention duration may benefit the 
physiological changes induced by exercise adaptations, 
reflecting a higher effect on echocardiographic and car-
diopulmonary function variables. On the other hand, 
this trial tries to reproduce the reality of clinical prac-
tice with all its sources of heterogeneity.
Prevention of cardiotoxicity through an exercise-
based CR program would have a high clinical impact 
[12, 29, 43]. The positive results of this study would be 
easily transferable to clinical practice in centers that 
have CR programs, establishing a new treatment indi-
cation and providing collaborative support between 
cardiology, oncology and rehabilitation. The proposed 
research question is concrete, with relevant clinical 
implications and achievable with low risk and reason-
able investment of resources.
Adaptations due to COVID‑19 pandemic
Due to the situation resulting from the Covid-19 pan-
demic and to give continuity to the ONCORE project, 
some amendments are incorporated to guarantee the 
safety of patients:
• Intervention in the EG: during Covid-19 pandemic, 
face-to-face supervised therapeutic exercise ses-
sions had to be stopped and telematic supervised 
exercise sessions are proposed. Exercise in the 
aerobic-anaerobic transition zone performed on 
a cycle ergometer or treadmill would be replaced 
by 14 min interval circuit of 3 series of 5 exercises, 
with 40  s of work and 10 of rest. This adaptation 
adds 10  min for strengthening and mobility exer-
cises.
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• Experimental group during the pandemic will be a 
subgroup that would also be analyzed independently.
• Assessment: cardiopulmonary function assessment 
by CPET would have to be temporarily stopped as 
disinfection of ventilation systems cannot be ensured. 
The 6-min walking test (6MWT) would be used to 
estimate peak VO2 [57].
• Exclusion criteria: a new exclusion criterion would be 
added: “Patients without possibility to join the telem-
atic exercise sessions”.
• Satisfaction questionnaire: questions related with 
telematic supervised exercise would be include.
Trial status
Recruitment for the study commenced in August 2018 
and is expected to be completed by March 1st, 2021, con-
sidering the withdrawal of one center from the study.
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